Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders

Jun 21, 2016 8:00am EDT

Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor

Jun 08, 2016 8:00am EDT

Aptose Bioscience Reports Results for the First Quarter Ended March 31, 2016

May 10, 2016 4:15pm EDT

Aptose To Release First Quarter Ended March 31, 2016 Financial Results and Hold Conference Call on May 10, 2016

May 02, 2016 8:00am EDT

Aptose Reports Fourth Quarter and Year End 2015 Results

Mar 29, 2016 4:10pm EDT

Aptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016

Mar 14, 2016 8:00am EDT

Aptose to Participate in Upcoming Investor Conferences

Mar 03, 2016 5:00pm EST

Aptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference

Feb 18, 2016 5:00pm EST

Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting

Dec 03, 2015 8:00am EST

Aptose Biosciences to Participate in Upcoming Investor Conferences

Nov 30, 2015 5:00pm EST
RSS
  • Prev
    • 1...
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences